| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8454569 | Lung Cancer | 2016 | 8 Pages |
Abstract
Sonidegib 800Â mg daily was the MTD when administered with EP. Further genomic characterization of exceptional responders may reveal clinically relevant predictive biomarkers that could tailor use in patients most likely to benefit.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
M. Catherine Pietanza, Anya M. Litvak, Anna M. Varghese, Lee M. Krug, Martin Fleisher, Jerrold B. Teitcher, Andrei I. Holodny, Cami S. Sima, Kaitlin M. Woo, Kenneth K. Ng, Helen H. Won, Michael F. Berger, Mark G. Kris, Charles M. Rudin,